4.6 Article

Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study

Journal

VALUE IN HEALTH
Volume 16, Issue 1, Pages 31-38

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jval.2012.08.2212

Keywords

absenteeism; chronic migraine; cost; episodic migraine; lost productive time; migraine; presenteeism

Funding

  1. Ortho-McNeil Neurologics, Inc., Titusville, NJ
  2. Allergan, Inc., Irvine, CA
  3. National Headache Foundation
  4. Allergan Pharmaceuticals
  5. GlaxoSmithKline
  6. ENDO Pharmaceuticals
  7. MAP Pharmaceuticals
  8. OrthoMcNeil
  9. Merck, Inc.
  10. Novartis
  11. Iroko Pharmaceuticals
  12. Minster
  13. Neuralieve
  14. Pfizer
  15. National Institutes of Health

Ask authors/readers for more resources

Objective: To quantify the cost differences and predictors of lost productive time (LPT) in persons with chronic migraine (CM) and episodic migraine (EM). Methods: The American Migraine Prevalence and Prevention (AMPP) study is a US national longitudinal survey of severe headache. Cost estimates were obtained via U.S. Census income data. To elucidate the unique predictors of LPT, the optimal distribution for modeling was determined. Zero inflation models for LPT were predicted from sociodemographics, headache features, characteristics and disability, medication use, and depression. The interaction between headache status and age was the primary effect of interest. Results: The eligible sample included 6329 persons with EM and 374 persons with CM. Men with CM aged 45 to 54 years cost employers nearly $200 per week more than do their EM counterparts. Likewise, for women, costs were higher for CM, with the cost differential between EM and CM being $90 per week. After comprehensive adjustment, increases in LPT with age were significantly higher in CM than in EM (rate ratio 1.03; 95% confidence interval 1.01-1.05). When age was recoded to a decade, metric rates of LPT increased 25% more per decade for CM than for EM (rate ratio 1.25; 95% confidence interval 1.004-1.5). Conclusions: LPT is more costly and increases more rapidly for those with CM than for those with EM as age increases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available